Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 480

1.

Inhaled corticosteroid containing combinations and mortality in COPD.

Vestbo J, Fabbri L, Papi A, Petruzzelli S, Scuri M, Guasconi A, Vezzoli S, Singh D.

Eur Respir J. 2018 Sep 12. pii: 1801230. doi: 10.1183/13993003.01230-2018. [Epub ahead of print] No abstract available.

PMID:
30209195
2.

Inhaled corticosteroids in COPD: Friend or foe?

Agusti A, Fabbri LM, Singh D, Vestbo J, Celli B, Franssen FM, Rabe KF, Papi A.

Eur Respir J. 2018 Sep 6. pii: 1801219. doi: 10.1183/13993003.01219-2018. [Epub ahead of print] Review.

PMID:
30190269
3.

Childhood Asthma, Lung Function Trajectories, and Chronic Obstructive Pulmonary Disease: An Additional Step Forward.

Vestbo J.

Ann Am Thorac Soc. 2018 Sep;15(9):1030-1031. doi: 10.1513/AnnalsATS.201807-440ED. No abstract available.

PMID:
30168747
4.

Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease.

Adamson PD, Anderson JA, Brook RD, Calverley PMA, Celli BR, Cowans NJ, Crim C, Dixon IJ, Martinez FJ, Newby DE, Vestbo J, Yates JC, Mills NL.

J Am Coll Cardiol. 2018 Sep 4;72(10):1126-1137. doi: 10.1016/j.jacc.2018.06.051.

5.

Diagnostic performance of clinical characteristics to detect airflow limitation in people living with HIV and in uninfected controls.

Ronit A, Benfield T, Mocroft A, Gerstoft J, Nordestgaard BG, Vestbo J, Nielsen SD; Copenhagen Co-morbidity in HIV Infection (COCOMO) Study Group.

HIV Med. 2018 Aug 30. doi: 10.1111/hiv.12669. [Epub ahead of print]

PMID:
30160344
6.

Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial.

Byrd JB, Newby DE, Anderson JA, Calverley PMA, Celli BR, Cowans NJ, Crim C, Martinez FJ, Vestbo J, Yates J, Brook RD; SUMMIT Investigators.

Eur Heart J. 2018 Sep 1;39(33):3128-3134. doi: 10.1093/eurheartj/ehy451.

PMID:
30101300
7.

Whole exome sequencing analysis in severe chronic obstructive pulmonary disease.

Qiao D, Ameli A, Prokopenko D, Chen H, Kho AT, Parker MM, Morrow J, Hobbs BD, Liu Y, Beaty TH, Crapo JD, Barnes KC, Nickerson DA, Bamshad M, Hersh CP, Lomas DA, Agusti A, Make BJ, Calverley PMA, Donner CF, Wouters EF, Vestbo J, Paré PD, Levy RD, Rennard SI, Tal-Singer R, Spitz MR, Sharma A, Ruczinski I, Lange C, Silverman EK, Cho MH; NHLBI Exome Sequencing Project, University of Washington Center for Mendelian Genomics, Lung GO, COPDGene Investigators.

Hum Mol Genet. 2018 Jul 27. doi: 10.1093/hmg/ddy269. [Epub ahead of print]

PMID:
30060175
8.

Patient-reported outcomes with initiation of fluticasone furoate/vilanterol versus continuing usual care in the Asthma Salford Lung Study.

Svedsater H, Jones R, Bosanquet N, Jacques L, Lay-Flurrie J, Leather DA, Vestbo J, Collier S, Woodcock A.

Respir Med. 2018 Aug;141:198-206. doi: 10.1016/j.rmed.2018.06.003. Epub 2018 Jun 6.

9.

Computed tomography quantification of emphysema in people living with HIV and uninfected controls.

Ronit A, Kristensen T, Hoseth VS, Abou-Kassem D, Kühl JT, Benfield T, Gerstoft J, Afzal S, Nordestgaard BG, Lundgren JD, Vestbo J, Kofoed KF, Nielsen SD; Copenhagen Comorbidity in HIV Infection (COCOMO) study group.

Eur Respir J. 2018 Jul 19;52(1). pii: 1800296. doi: 10.1183/13993003.00296-2018. Print 2018 Jul.

PMID:
29880654
10.

Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease.

Yun JH, Lamb A, Chase R, Singh D, Parker MM, Saferali A, Vestbo J, Tal-Singer R, Castaldi PJ, Silverman EK, Hersh CP; COPDGene and ECLIPSE Investigators.

J Allergy Clin Immunol. 2018 Jun;141(6):2037-2047.e10. doi: 10.1016/j.jaci.2018.04.010. Epub 2018 Apr 28.

PMID:
29709670
11.

Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study.

Vogelmeier CF, Chapman KR, Miravitlles M, Roche N, Vestbo J, Thach C, Banerji D, Fogel R, Patalano F, Olsson P, Kostikas K, Wedzicha JA.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 10;13:1125-1134. doi: 10.2147/COPD.S160011. eCollection 2018.

12.

Left ventricular volume and wall stress are linked to lung function impairment in COPD.

Alter P, Jörres RA, Watz H, Welte T, Gläser S, Schulz H, Bals R, Karch A, Wouters EFM, Vestbo J, Young D, Vogelmeier CF.

Int J Cardiol. 2018 Jun 15;261:172-178. doi: 10.1016/j.ijcard.2018.02.074.

PMID:
29657040
13.

Blood eosinophil count and risk of pneumonia hospitalisations in individuals with COPD.

Vedel-Krogh S, Nordestgaard BG, Lange P, Vestbo J, Nielsen SF.

Eur Respir J. 2018 May 24;51(5). pii: 1800120. doi: 10.1183/13993003.00120-2018. Print 2018 May.

PMID:
29650563
14.

The emerging Chinese COPD epidemic.

Vestbo J, Mathioudakis AG.

Lancet. 2018 Apr 28;391(10131):1642-1643. doi: 10.1016/S0140-6736(18)30859-6. Epub 2018 Apr 9. No abstract available.

PMID:
29650249
15.

Effectiveness versus efficacy trials in COPD: how study design influences outcomes and applicability.

Woodcock A, Boucot I, Leather DA, Crawford J, Collier S, Bakerly ND, Hilton E, Vestbo J.

Eur Respir J. 2018 Feb 21;51(2). pii: 1701531. doi: 10.1183/13993003.01531-2017. Print 2018 Feb.

PMID:
29467200
16.

Young and middle-aged adults with airflow limitation according to lower limit of normal but not fixed ratio have high morbidity and poor survival: a population-based prospective cohort study.

Çolak Y, Afzal S, Nordestgaard BG, Vestbo J, Lange P.

Eur Respir J. 2018 Mar 29;51(3). pii: 1702681. doi: 10.1183/13993003.02681-2017. Print 2018 Mar.

PMID:
29449425
17.

Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial.

Kunisaki KM, Dransfield MT, Anderson JA, Brook RD, Calverley PMA, Celli BR, Crim C, Hartley BF, Martinez FJ, Newby DE, Pragman AA, Vestbo J, Yates JC, Niewoehner DE; SUMMIT Investigators.

Am J Respir Crit Care Med. 2018 Jul 1;198(1):51-57. doi: 10.1164/rccm.201711-2239OC.

PMID:
29442524
18.

Emphysema and extrapulmonary tissue loss in COPD: a multi-organ loss of tissue phenotype.

Celli BR, Locantore N, Tal-Singer R, Riley J, Miller B, Vestbo J, Yates JC, Silverman EK, Owen CA, Divo M, Pinto-Plata V, Wouters EFM, Faner R, Agusti A; ECLIPSE Study Investigators.

Eur Respir J. 2018 Feb 7;51(2). pii: 1702146. doi: 10.1183/13993003.02146-2017. Print 2018 Feb.

PMID:
29437944
19.

Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.

Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, Guasconi A, Montagna I, Vezzoli S, Petruzzelli S, Scuri M, Roche N, Singh D.

Lancet. 2018 Mar 17;391(10125):1076-1084. doi: 10.1016/S0140-6736(18)30206-X. Epub 2018 Feb 9. Erratum in: Lancet. 2018 Feb 26;:.

PMID:
29429593
20.

The revised GOLD 2017 COPD categorization in relation to comorbidities.

Kahnert K, Alter P, Young D, Lucke T, Heinrich J, Huber RM, Behr J, Wacker M, Biertz F, Watz H, Bals R, Welte T, Wirtz H, Herth F, Vestbo J, Wouters EF, Vogelmeier CF, Jörres RA.

Respir Med. 2018 Jan;134:79-85. doi: 10.1016/j.rmed.2017.12.003. Epub 2017 Dec 5.

21.

Long-Acting β-Agonist/Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease with Cardiovascular Disease or Risk: A Factorial Analysis of the SUMMIT Clinical Trial.

Celli B, Anderson JA, Brook R, Calverley P, Crim C, Holmes AP, Martinez FJ, Newby DE, Yates J, Vestbo J; SUMMIT Investigators.

Am J Respir Crit Care Med. 2018 Jun 15;197(12):1641-1644. doi: 10.1164/rccm.201710-2052LE. No abstract available.

PMID:
29412688
22.

At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease.

Martinez FJ, Han MK, Allinson JP, Barr RG, Boucher RC, Calverley PMA, Celli BR, Christenson SA, Crystal RG, Fagerås M, Freeman CM, Groenke L, Hoffman EA, Kesimer M, Kostikas K, Paine R 3rd, Rafii S, Rennard SI, Segal LN, Shaykhiev R, Stevenson C, Tal-Singer R, Vestbo J, Woodruff PG, Curtis JL, Wedzicha JA.

Am J Respir Crit Care Med. 2018 Jun 15;197(12):1540-1551. doi: 10.1164/rccm.201710-2028PP. No abstract available.

PMID:
29406779
23.

β-Blocker Therapy and Clinical Outcomes in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. An Observational Substudy of SUMMIT.

Dransfield MT, McAllister DA, Anderson JA, Brook RD, Calverley PMA, Celli BR, Crim C, Gallot N, Martinez FJ, Scanlon PD, Yates J, Vestbo J, Newby DE; SUMMIT Investigators.

Ann Am Thorac Soc. 2018 May;15(5):608-614. doi: 10.1513/AnnalsATS.201708-626OC.

PMID:
29406772
24.

Cigarette smoking and response to inhaled corticosteroids in COPD.

Bhatt SP, Anderson JA, Brook RD, Calverley PMA, Celli BR, Cowans NJ, Crim C, Martinez FJ, Newby DE, Vestbo J, Yates JC, Dransfield MT.

Eur Respir J. 2018 Jan 18;51(1). pii: 1701393. doi: 10.1183/13993003.01393-2017. Print 2018 Jan. No abstract available.

PMID:
29348179
25.

Airflow limitation in people living with HIV and matched uninfected controls.

Ronit A, Lundgren J, Afzal S, Benfield T, Roen A, Mocroft A, Gerstoft J, Nordestgaard BG, Vestbo J, Nielsen SD; Copenhagen Co-morbidity in HIV infection (COCOMO) study group.

Thorax. 2018 May;73(5):431-438. doi: 10.1136/thoraxjnl-2017-211079. Epub 2018 Jan 13.

PMID:
29331988
26.

Pulmonary rehabilitation for patients with COPD during and after an exacerbation-related hospitalisation: back to the future?

Wilson KC, Krishnan JA, Sliwinski P, Criner GJ, Miravitlles M, Hurst JR, Calverley PMA, Albert RK, Rigau D, Tonia T, Vestbo J, Papi A, Rabe KF, Anzueto A, Wedzicha JA.

Eur Respir J. 2018 Jan 11;51(1). pii: 1702577. doi: 10.1183/13993003.02577-2017. Print 2018 Jan. No abstract available.

PMID:
29326324
27.

Biomarkers of collagen turnover are related to annual change in FEV1 in patients with chronic obstructive pulmonary disease within the ECLIPSE study.

Leeming DJ, Byrjalsen I, Sand JMB, Bihlet AR, Lange P; Evaluation of COPD Longitudinally to Identify Surrogate Endpoints (ECLIPSE) study investigators, Thal-Singer R, Miller BE, Karsdal MA, Vestbo J.

BMC Pulm Med. 2017 Dec 4;17(1):164. doi: 10.1186/s12890-017-0505-4.

28.

Management of Dyspnea and Anxiety in Chronic Obstructive Pulmonary Disease: A Critical Review.

Yohannes AM, Junkes-Cunha M, Smith J, Vestbo J.

J Am Med Dir Assoc. 2017 Dec 1;18(12):1096.e1-1096.e17. doi: 10.1016/j.jamda.2017.09.007. Epub 2017 Nov 3. Review.

PMID:
29108885
29.

Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.

Singh D, Corradi M, Spinola M, Papi A, Usmani OS, Scuri M, Petruzzelli S, Vestbo J.

Int J Chron Obstruct Pulmon Dis. 2017 Oct 6;12:2917-2928. doi: 10.2147/COPD.S146822. eCollection 2017. Review.

30.

Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial.

Crim C, Calverley PMA, Anderson JA, Holmes AP, Kilbride S, Martinez FJ, Brook RD, Newby DE, Yates JC, Celli BR, Vestbo J; SUMMIT investigators.

Respir Med. 2017 Oct;131:27-34. doi: 10.1016/j.rmed.2017.07.060. Epub 2017 Aug 1.

PMID:
28947039
31.

Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial.

Woodcock A, Vestbo J, Bakerly ND, New J, Gibson JM, McCorkindale S, Jones R, Collier S, Lay-Flurrie J, Frith L, Jacques L, Fletcher JL, Harvey C, Svedsater H, Leather D; Salford Lung Study Investigators.

Lancet. 2017 Nov 18;390(10109):2247-2255. doi: 10.1016/S0140-6736(17)32397-8. Epub 2017 Sep 10. Erratum in: Lancet. 2017 Nov 18;390(10109):e40. Lancet. 2018 Feb 3;391(10119):430.

PMID:
28903864
32.

The prognostic significance of lung function in stable heart failure outpatients.

Plesner LL, Dalsgaard M, Schou M, Køber L, Vestbo J, Kjøller E, Iversen K.

Clin Cardiol. 2017 Nov;40(11):1145-1151. doi: 10.1002/clc.22802. Epub 2017 Sep 13.

33.

Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline.

Wedzicha JA, Calverley PMA, Albert RK, Anzueto A, Criner GJ, Hurst JR, Miravitlles M, Papi A, Rabe KF, Rigau D, Sliwinski P, Tonia T, Vestbo J, Wilson KC, Krishnan JA.

Eur Respir J. 2017 Sep 9;50(3). pii: 1602265. doi: 10.1183/13993003.02265-2016. Print 2017 Sep.

PMID:
28889106
34.

Incidental lung cancers and positive computed tomography images in people living with HIV.

Ronit A, Kristensen T, Klitbo DM, Gelpi M, Kalhauge A, Benfield T, Gerstoft J, Lundgren J, Vestbo J, Kofoed KF, Nielsen SD.

AIDS. 2017 Sep 10;31(14):1973-1977. doi: 10.1097/QAD.0000000000001600.

PMID:
28857778
35.

Susceptibility to exacerbation in COPD.

Hurst JR, Anzueto A, Vestbo J.

Lancet Respir Med. 2017 Sep;5(9):e29. doi: 10.1016/S2213-2600(17)30307-7. No abstract available.

PMID:
28853400
36.

Psychometric Properties of the COPD-Specific Beliefs About Medicine Questionnaire in an Outpatient Population: A Rasch-Analysis.

Topp M, Vestbo J, Mortensen EL.

Chronic Obstr Pulm Dis. 2016 Sep 2;3(4):748-757. doi: 10.15326/jcopdf.3.4.2016.0134.

37.

A multi-center randomized, controlled, open-label trial evaluating the effects of eosinophil-guided corticosteroid-sparing therapy in hospitalised patients with COPD exacerbations - The CORTICO steroid reduction in COPD (CORTICO-COP) study protocol.

Sivapalan P, Moberg M, Eklöf J, Janner J, Vestbo J, Laub RR, Browatzki A, Armbruster K, Wilcke JT, Seersholm N, Weinreich UM, Titlestad IL, Andreassen HF, Ulrik CS, Bødtger U, Nielsen TL, Hansen EF, Jensen JUS.

BMC Pulm Med. 2017 Aug 15;17(1):114. doi: 10.1186/s12890-017-0458-7.

38.

Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk.

Calverley PMA, Anderson JA, Brook RD, Crim C, Gallot N, Kilbride S, Martinez FJ, Yates J, Newby DE, Vestbo J, Wise R, Celli BR; SUMMIT (Study to Understand Mortality and Morbidity) Investigators.

Am J Respir Crit Care Med. 2018 Jan 1;197(1):47-55. doi: 10.1164/rccm.201610-2086OC.

PMID:
28737971
39.

The Association of Depressive Symptoms With Rates of Acute Exacerbations in Patients With COPD: Results From a 3-year Longitudinal Follow-up of the ECLIPSE Cohort.

Yohannes AM, Mülerová H, Lavoie K, Vestbo J, Rennard SI, Wouters E, Hanania NA.

J Am Med Dir Assoc. 2017 Nov 1;18(11):955-959.e6. doi: 10.1016/j.jamda.2017.05.024. Epub 2017 Jul 18.

PMID:
28733182
40.

Taken to task: what is and is not an appropriate response to an ERS guidelines task force?

Joos G, Bush A, Burghuber OC, Robalo Cordeiro C, Gaga M, Gibson GJ, Gratziou C, Rigau D, Rohde G, Smyth D, Stolz D, Tonia T, Vestbo J, Welte T, Brusselle G, Miravitlles M.

Eur Respir J. 2017 Jul 13;50(1). pii: 1700952. doi: 10.1183/13993003.00952-2017. Print 2017 Jul. No abstract available.

PMID:
28705948
41.

Global Initiative for Chronic Obstructive Lung Disease (GOLD) 20th Anniversary: a brief history of time.

Rodriguez-Roisin R, Rabe KF, Vestbo J, Vogelmeier C, Agustí A; all previous and current members of the Science Committee and the Board of Directors of GOLD (goldcopd.org/committees/).

Eur Respir J. 2017 Jul 5;50(1). pii: 1700671. doi: 10.1183/13993003.00671-2017. Print 2017 Jul. No abstract available.

PMID:
28679615
42.

Erratum to "Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary" [Arch Bronconeumol. 2017;53:128-49].

Vogelmeier CF, Criner GJ, Martínez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DMG, Varela MVL, Nishimura M, Roche N, Rodríguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A.

Arch Bronconeumol. 2017 Jul;53(7):411-412. doi: 10.1016/j.arbres.2017.06.001. English, Spanish. No abstract available.

43.

The TRINITY study: Twitter discussion from a respirology journal club - Authors' reply.

Vestbo J; TRINITY investigators.

Lancet Respir Med. 2017 Jul;5(7):e26. doi: 10.1016/S2213-2600(17)30230-8. No abstract available.

PMID:
28664866
44.

Clinical trial research in focus: time to reflect on the design of exacerbation trials in COPD.

Vestbo J, Woodcock A.

Lancet Respir Med. 2017 Jun;5(6):466-468. doi: 10.1016/S2213-2600(17)30177-7. Epub 2017 May 26. No abstract available.

PMID:
28664846
45.

Exposure Interaction: A Lifelong Phenomenon with Relevance to Chronic Obstructive Pulmonary Disease.

Vestbo J, Lange P.

Am J Respir Crit Care Med. 2017 Oct 15;196(8):947-948. doi: 10.1164/rccm.201705-1035ED. No abstract available.

PMID:
28640650
46.

Fletcher and Peto 40 Years On. A Tribute and Reflection.

Vestbo J, Lange P.

Am J Respir Crit Care Med. 2017 Jun 1;195(11):1420-1422. doi: 10.1164/rccm.201702-0346ED. No abstract available.

PMID:
28569577
47.

Triple Therapy in Chronic Obstructive Pulmonary Disease.

Singh D, Vestbo J.

Am J Respir Crit Care Med. 2017 Oct 15;196(8):1082-1083. doi: 10.1164/rccm.201704-0811LE. No abstract available.

PMID:
28534641
48.

COPD monocytes demonstrate impaired migratory ability.

Ravi AK, Plumb J, Gaskell R, Mason S, Broome CS, Booth G, Catley M, Vestbo J, Singh D.

Respir Res. 2017 May 11;18(1):90. doi: 10.1186/s12931-017-0569-y.

49.

Cardiovascular risks in smokers treated with nicotine replacement therapy: a historical cohort study.

Dollerup J, Vestbo J, Murray-Thomas T, Kaplan A, Martin RJ, Pizzichini E, Pizzichini MMM, Burden A, Martin J, Price DB.

Clin Epidemiol. 2017 Apr 26;9:231-243. doi: 10.2147/CLEP.S127775. eCollection 2017.

50.

Stability of the frequent COPD exacerbator in the general population: A Danish nationwide register-based study.

Reilev M, Lykkegaard J, Halling A, Vestbo J, Søndergaard J, Pottegård A.

NPJ Prim Care Respir Med. 2017 Apr 17;27(1):25. doi: 10.1038/s41533-017-0029-7.

Supplemental Content

Loading ...
Support Center